Protagonist Therapeutics Q4 2023 Earnings Report $40.83 +0.14 (+0.34%) (As of 10:33 AM ET) Earnings HistoryForecast Protagonist Therapeutics EPS ResultsActual EPS$0.44Consensus EPS $0.05Beat/MissBeat by +$0.39One Year Ago EPSN/AProtagonist Therapeutics Revenue ResultsActual Revenue$60.00 millionExpected Revenue$60.00 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AProtagonist Therapeutics Announcement DetailsQuarterQ4 2023Date2/27/2024TimeAfter Market ClosesConference Call ResourcesPress ReleasePTGX Earnings HistoryPowered by AI Crypto Tool Could Send One Coin SOARING… (Ad)The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Protagonist Therapeutics Earnings HeadlinesPromising Prospects for Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Efficacy and Competitive EdgeDecember 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda PartnershipDecember 11, 2024 | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 18, 2024 | Crypto Swap Profits (Ad)HC Wainwright Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX)December 11, 2024 | americanbankingnews.comProtagonist Therapeutics announces data from REVIVE study at ASHDecember 10, 2024 | markets.businessinsider.comBMO Capital Markets Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)December 8, 2024 | americanbankingnews.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX), a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
